Bentham Science Free Trial in the Shenyang Pharmaceutical University | Free Trial ends on June 20th, 2021

It is our pleasure to inform you that Bentham Science Publishers has activated 2 months trial subscription for Shenyang Pharmaceutical University. The trial subscription covers access to Bentham Science journals and Books content.

Bentham Science uses the platforms Eurekaselect (our proprietary platform) & Ingenta Connect (a well-known content gateway) for offering journal and Books trials. The trial has been activated on both platforms, Eureka & Ingenta. (Note: Book trials are only available on Eurekaselect)

Members of your library can view all Bentham Science journal issues (2000-2020) in full text and eBook content which will allow your library users to access our catalog of over 800 eBooks for the same duration via the following URLs:

1.  https://eurekaselect.net

2. http://www.ingentaconnect.com/content/ben

Trial Duration: 2 Months
End Date: June 22nd, 2021

Online Trial Access Procedure:

To access the free trial offer, you do not need to insert a user ID or a password. Instead you can access the following URL by logging through the library’s registered IP Addresses in your browser:

Ingenta Connect: http://www.ingentaconnect.com/content/ben

Eureka Select:
For Journals: https://eurekaselect.net/bypublication
For eBooks:  https://eurekaselect.net/bybook

Free Trial Announcement Among The Users Of Your Library/Institution

We will appreciate it if you could announce the availability of this free trial to all the members of your library/institution. By alerting your members, maximum people would be able to benefit from access to our top class scientific content.

If you require further assistance, please contact us at: hermain@benthamscience.net CC: faizan@benthamscience.net

Read what our Authors have to say about publishing in our Journal – Testimonial by Dr. Bhupesh Sharma

Contributed Article: PDE3 Inhibition by Cilostazol Ameliorated Behavioral and Biochemical Deficits in Prenatal Alcohol Induced Experimental ADHD

Author: Bhupesh Sharma

Affiliation: Department of Pharmacology, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, India

 H- Index : 22

Country : India 

 

Bentham Science Free Trial in the Capital Medical University | Free Trial ends on June 22nd, 2021

It is our pleasure to inform you that Bentham Science Publishers has activated 2 months trial subscription for Capital Medical University. The trial subscription covers access to Bentham Science journals and Books content.

Bentham Science uses the platforms Eurekaselect (our proprietary platform) & Ingenta Connect (a well-known content gateway) for offering journal and Books trials. The trial has been activated on both platforms, Eureka & Ingenta. (Note: Book trials are only available on Eurekaselect)

Members of your library can view all Bentham Science journal issues (2000-2020) in full text and eBook content which will allow your library users to access our catalog of over 800 eBooks for the same duration via the following URLs:

1.  https://eurekaselect.net

2. http://www.ingentaconnect.com/content/ben

Trial Duration: 2 Months
End Date: June 22nd, 2021

Online Trial Access Procedure:

To access the free trial offer, you do not need to insert a user ID or a password. Instead you can access the following URL by logging through the library’s registered IP Addresses in your browser:

Ingenta Connect: http://www.ingentaconnect.com/content/ben

Eureka Select:
For Journals: https://eurekaselect.net/bypublication
For eBooks:  https://eurekaselect.net/bybook

Free Trial Announcement Among The Users Of Your Library/Institution

We will appreciate it if you could announce the availability of this free trial to all the members of your library/institution. By alerting your members, maximum people would be able to benefit from access to our top class scientific content.

If you require further assistance, please contact us at: hermain@benthamscience.net CC: faizan@benthamscience.net

Press Release: Novel pharmacological strategies to treat alcoholism. Focus on epigenetics

This article by Dr. F. David Rodriguez is published in the journal, Current Pharmaceutical Design, 2021

Abusive alcohol drinking considerably impacts human health. Alcoholism, better defined as Alcohol Use Disorders (AUD), includes a group of pathological entities related to alcohol-induced damage. Individuals with AUD exhibit compulsive alcohol drinking and negative emotional states when alcohol drinking ceases. In the most severe AUD forms, the individuals lose control over consumption despite a decided will to stop. Some controversial issues have arisen as to whether the definition of AUD can help to delimit and characterize clinical entities related to abusive alcohol ingestion.

The World Health Organization (WHO) reports that approximately 3,3 million people (5,9% of global deaths) die yearly because of harmful alcohol consumption (According to WHO, as of 4 February 2021, there have been 2,25 million deaths caused by COVID-19, globally). Besides, alcohol is directly responsible for 5 % of disabling diseases and injuries worldwide.

Authorized agencies have officially approved very few pharmacological treatments to treat AUD (for example, disulfiram, opioid antagonists, acamprosate, baclofen, or topiramate). Many patients are reluctant to treatment for different reasons based on their features (age, gender, ethnicity, genetic and epigenetic background) and their alcohol drinking behavior.

Currently, no silver bullet shall rescue humankind from the burden of alcohol on health. Notwithstanding, a better understanding of ethanol’s repercussion on molecular cell targets is imperious to plan out pharmacological strategies that ameliorate or block alcohol detriment.

Despite limited favorable results, efforts continue to find drugs acting on causes and effects observed in AUD, including relapse, withdrawal, stress, or anxiety. Nowadays, clinical studies in phases I and II explore the effectiveness of drugs in AUD treatment. Examples of compounds investigated are glutamate and GABA modulators, neuropeptide antagonists, or regulators of neuroimmune responses. Some drugs administered for the treatment of mental disorders have proved efficient in the treatment of AUD. For example, aripiprazole, an antipsychotic drug, and agomelatine, a melatonergic antidepressant, showed beneficial effects by preventing alcohol relapse and craving. The influence of alcohol on epigenetic mechanisms is a relatively new explored field that offers new avenues for research in the field. The term epigenetics includes chemical changes in DNA, proteins (histones, mainly), mRNAs, and non-coding RNAs with regulatory capacity that control gene expression.

This study provides an in-depth review of recent research that reveals the impact of alcohol on the biochemical mechanisms responsible for epigenetic control within cells. Besides, it analyzes candidate drugs that may counteract the impact of alcohol on epigenetic mechanisms and serve to advance new and tailored pharmacological treatments. Research carried out in animal models and humans (with the obvious ethical limitations imposed on human research) provides valuable information on the epigenetic regulatory processes intercepted by alcohol. The design and laboratory synthesis of new drugs aimed at specific molecular targets offers significant advances in this field. Read the full Press Release to find out more: https://www.eurekalert.org/pub_releases/2021-03/bsp-nps033121.php

For more information about the journal, please visit: https://benthamscience.com/journals/current-alzheimer-research/

New Issue – Current Alzheimer Research Volume 18 Issue 1

AIMS & SCOPE

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

Articles from the Journal 

For more details on the articles, please visit: https://www.eurekaselect.com/node/643/current-alzheimer-research/issue/18/2965/1/10582

%d bloggers like this: